In the latest quarter, 11 analysts provided ratings for Nevro NVRO, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Nevro (NVRO) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

Nevro (NVRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a definitive agreement for Globus Medical to acquire all its ...

Piper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the company entered into a definitive agreement for Globus ...